Recombinant leptin analogue
Metreleptin
Brand names: Myalepta
Adult dose
Dose: Weight-based SC OD; refer to BNF/SmPC
Route: SC
Frequency: OD
Clinical pearls
- Generalised lipodystrophy / partial lipodystrophy with severe metabolic abnormality — specialist endocrine
Contraindications
- General lipodystrophy with obesity
- Hypersensitivity
Side effects
- Hypoglycaemia
- Lymphoma (theoretical — registry monitoring)
- Pancreatitis
- Anti-drug antibodies
- Injection site reactions
Interactions
- Insulin/sulfonylureas (hypoglycaemia — adjust)
- Hormonal contraceptives (efficacy may decrease)
Monitoring
- HbA1c
- Lipids
- Lymph nodes
- Anti-drug antibodies
Reference: BNF; NICE HST14; SmPC; https://bnf.nice.org.uk/drugs/metreleptin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016